Stage IV Esophageal Cancer: Room for Improvement? | ScholarDeck

Paper

Stage IV Esophageal Cancer: Room for Improvement?

New research · Thoracic Surgery

Journal of laparoendoscopic & advanced surgical techniques. Part A · 10h

Cohort studyJournal of laparoendoscopic & advanced surgical techniques. Part A· Sep 2026

Stage IV Esophageal Cancer: Room for Improvement?

Pamela Milito, Stefano Siboni, Serena Grimaldi … Emanuele Asti

Esophageal SurgeryCohort studyQ3IF 1.2

Median survival much longer for stage IV-A than stage IV-B esophageal cancer after surgery

Stage IV Esophageal Cancer: Room for Improvement?

Pamela Milito … Emanuele Asti

Journal of laparoendoscopic & advanced surgical techniques · Sep 2026 · Q3 in Surgery

Background

Esophageal cancer has a very poor prognosis in advanced stages, with 5-year survival rates below 6% in stage IV disease.

Purpose

This study aimed to assess short- and long-term outcomes in patients undergoing surgery for pathological stage IV esophageal cancer.

Methods

Were divided into stage IV-A ( n = 39) and stage IV-B ( n = 21), all of whom were oligometastatic according to the OMEC classification.

n = 39

Results

IV-A patients lived more than twice as long after surgery

Stage IV-A

18months

Stage IV-B

8months

More results

Median age was 63.5 years, and 61.7% of patients were male.

Postoperative morbidity was 43.3%, and in-hospital mortality rate of 5%, showing no significant differences between groups.

Among stage IV-B patients, survival differed according to metastatic site, with better outcomes in nodal-only disease.

“

Conclusion

Esophagectomy may be feasible in highly selected stage IV patients, offering meaningful survival in stage IV-A cases, while outcomes in stage IV-B remain limited and influenced by metastatic pattern.

0 comments

No comments yet. Be the first.

ScholarDeck.

Join the discussion on this paper

Create your profile

Related papers

Latest Foundational

poor responders recurred locally, not distantly, after surgery

87.5% vs. 71.0%

neoadjuvant patients were far more likely to be alive at 2 years

achieving textbook outcome lowers mortality risk after gastrectomy

open surgery raised the odds of early conduit emptying delay

neoadjuvant chemoimmunotherapy nearly doubled the odds of postoperative pneumonia vs surgery alone

Leaks requiring reoperation were linked to about 50% higher adjusted risk of death

esophagectomy trended toward better survival, but not significantly

score correctly separates high from low risk patients most of the time